Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors
Michael S. Cohen,Chao Zhang,Kevan M. Shokat,Jack Taunton*
The active sites of 491 human protein kinase domains are highlyconserved, which makes the design of selective inhibitors aformidable challenge. We used a structural bioinformatics approachto identify two selectivity filters, a threonine and a cysteine,at defined positions in the active site of p90 ribosomal proteinS6 kinase (RSK). A fluoromethylketone inhibitor, designed toexploit both selectivity filters, potently and selectively inactivatedRSK1 and RSK2 in mammalian cells. Kinases with only one selectivityfilter were resistant to the inhibitor, yet they became sensitizedafter genetic introduction of the second selectivity filter.Thus, two amino acids that distinguish RSK from other proteinkinases are sufficient to confer inhibitor sensitivity.
Program in Chemistry and Chemical Biology, and Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94143-2280, USA.
* To whom correspondence should be addressed. E-mail: taunton{at}cmp.ucsf.edu
The PKARI{alpha} Subunit of Protein Kinase A Modulates the Activation of p90RSK1 and Its Function.
D. Chaturvedi, M. S. Cohen, J. Taunton, and T. B. Patel (2009)
J. Biol. Chem.
284, 23670-23681
|Abstract »|Full Text »|PDF »
Mechanism of Sustained Activation of Ribosomal S6 Kinase (RSK) and ERK by Kaposi Sarcoma-associated Herpesvirus ORF45: MULTIPROTEIN COMPLEXES RETAIN ACTIVE PHOSPHORYLATED ERK AND RSK AND PROTECT THEM FROM DEPHOSPHORYLATION.
Fibroblast Growth Factor Receptor 1-Transformed Mammary Epithelial Cells Are Dependent on RSK Activity for Growth and Survival.
W. Xian, L. Pappas, D. Pandya, L. M. Selfors, P. W. Derksen, M. de Bruin, N. S. Gray, J. Jonkers, J. M. Rosen, and J. S. Brugge (2009)
Cancer Res.
69, 2244-2251
|Abstract »|Full Text »|PDF »
R. T. Strachan, D. J. Sheffler, B. Willard, M. Kinter, J. G. Kiselar, and B. L. Roth (2009)
J. Biol. Chem.
284, 5557-5573
|Abstract »|Full Text »|PDF »
Chemical and Pathway Proteomics: Powerful Tools for Oncology Drug Discovery and Personalized Health Care.
U. Kruse, M. Bantscheff, G. Drewes, and C. Hopf (2008)
Mol. Cell. Proteomics
7, 1887-1901
|Abstract »|Full Text »|PDF »
Reactive Oxygen Species-Induced Activation of p90 Ribosomal S6 Kinase Prolongs Cardiac Repolarization Through Inhibiting Outward K+ Channel Activity.
Z. Lu, J.-i. Abe, J. Taunton, Y. Lu, T. Shishido, C. McClain, C. Yan, S. P. Xu, T. M. Spangenberg, and H. Xu (2008)
Circ. Res.
103, 269-278
|Abstract »|Full Text »|PDF »
Epidermal Growth Factor Stimulates RSK2 Activation through Activation of the MEK/ERK Pathway and Src-dependent Tyrosine Phosphorylation of RSK2 at Tyr-529.
S. Kang, S. Dong, A. Guo, H. Ruan, S. Lonial, H. J. Khoury, T.-L. Gu, and J. Chen (2008)
J. Biol. Chem.
283, 4652-4657
|Abstract »|Full Text »|PDF »
Activation of p90 Ribosomal S6 Kinase by ORF45 of Kaposi's Sarcoma-Associated Herpesvirus and Its Role in Viral Lytic Replication.
Ribosomal S6 Kinase 2 Is a Key Regulator in Tumor Promoter Induced Cell Transformation.
Y.-Y. Cho, K. Yao, H.-G. Kim, B. S. Kang, D. Zheng, A. M. Bode, and Z. Dong (2007)
Cancer Res.
67, 8104-8112
|Abstract »|Full Text »|PDF »
RAS/ERK Signaling Promotes Site-specific Ribosomal Protein S6 Phosphorylation via RSK and Stimulates Cap-dependent Translation.
P. P. Roux, D. Shahbazian, H. Vu, M. K. Holz, M. S. Cohen, J. Taunton, N. Sonenberg, and J. Blenis (2007)
J. Biol. Chem.
282, 14056-14064
|Abstract »|Full Text »|PDF »
Evidence for Direct Regulation of Myocardial Na+/H+ Exchanger Isoform 1 Phosphorylation and Activity by 90-kDa Ribosomal S6 Kinase (RSK): Effects of the Novel and Specific RSK Inhibitor fmk on Responses to {alpha}1-Adrenergic Stimulation.
F. Cuello, A. K. Snabaitis, M. S. Cohen, J. Taunton, and M. Avkiran (2007)
Mol. Pharmacol.
71, 799-806
|Abstract »|Full Text »|PDF »
Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance.
Structural Analysis of Protein Kinase A Mutants with Rho-kinase Inhibitor Specificity.
S. Bonn, S. Herrero, C. B. Breitenlechner, A. Erlbruch, W. Lehmann, R. A. Engh, M. Gassel, and D. Bossemeyer (2006)
J. Biol. Chem.
281, 24818-24830
|Abstract »|Full Text »|PDF »
RSK and MSK in MAP kinase signalling..
C. Hauge and M. Frodin (2006)
J. Cell Sci.
119, 3021-3023
|Full Text »|PDF »
Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides..
A. Schirmer, J. Kennedy, S. Murli, R. Reid, and D. V. Santi (2006)
PNAS
103, 4234-4239
|Abstract »|Full Text »|PDF »